Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

BACKGROUND: B-cell-depleting therapies increase the risk of morbidity and mortality due to COVID-19. Evidence-based SARS-CoV-2 vaccination strategies for patients on B-cell-depleting therapies are scarce. We aimed to investigate humoral and cell-mediated immune responses to SARS-CoV-2 mRNA-based vac...

Descripción completa

Detalles Bibliográficos
Autores principales: Moor, Matthias B, Suter-Riniker, Franziska, Horn, Michael P, Aeberli, Daniel, Amsler, Jennifer, Möller, Burkhard, Njue, Linet M, Medri, Cesare, Angelillo-Scherrer, Anne, Borradori, Luca, Radonjic-Hoesli, Susanne, Seyed Jafari, S Morteza, Chan, Andrew, Hoepner, Robert, Bacher, Vera Ulrike, Mani, Laila-Yasmin, Iype, Joseena Mariam, Hirzel, Cédric, Maurer, Britta, Sidler, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423431/
https://www.ncbi.nlm.nih.gov/pubmed/34514436
http://dx.doi.org/10.1016/S2665-9913(21)00251-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423431/
https://www.ncbi.nlm.nih.gov/pubmed/34514436
http://dx.doi.org/10.1016/S2665-9913(21)00251-4

Ejemplares similares